wire - news in brief

« BACK

Health



Results 1 - 50 of 1681.
1 2 3 4 5 ... 34 Next »


Environment - Health - 03.12.2019
"Climate Change is Becoming One of the Biggest Global Health Threats"
Climate change not only affects the environment, but also has significant consequences on global health.

Pharmacology - Health - 02.12.2019
Novartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platforms
Patients & Caregivers Healthcare Professionals Society & ESG With more than 140 abstracts, Novartis continues its leadership in hematology innovation   Data for MBG453, an innovative anti-TIM

Health - Pharmacology - 02.12.2019

Health - Pharmacology - 02.12.2019
Improving Tuberculosis Screening in Remote Areas
Improving Tuberculosis Screening in Remote Areas
Every year, 1.5 million people die from tuberculosis (TB) worldwide. Diagnosis and treatment is particularly difficult in remote rural areas.

Pharmacology - Health - 17.11.2019
Novartis PARAGON-HF analyses suggest Entresto benefit beyond HFrEF
Patients & Caregivers Healthcare Professionals Society & ESG Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compare

Pharmacology - Health - 15.11.2019
New Novartis medicine Adakveo (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Patients & Caregivers Healthcare Professionals Society & ESG Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications 1   Adakveo reduced the an

Pharmacology - Health - 15.11.2019
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Patients & Caregivers Healthcare Professionals Society & ESG If approved, Mayzent (siponimod) will be the first and only oral treatment specifically indicated for patients with active seconda

Health - Life Sciences - 13.11.2019
Award for project on Heart Transplantation
Award for project on Heart Transplantation
This year's Johanna Dürmüller-Bol DBMR Research Award of the Department for BioMedical Research (DBMR) of the University of Bern goes to Maria-Nieves Sanz.

Pharmacology - Health - 12.11.2019
New Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis
Patients & Caregivers Healthcare Professionals Society & ESG 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores

Health - Pharmacology - 12.11.2019
Sandoz presents real-world data showing effectiveness of Erelzi (etanercept-szzs) in rheumatic disease treatment
Patients & Caregivers Healthcare Professionals Society & ESG Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/AR

Pharmacology - Health - 11.11.2019
Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone
Roche today announced data from the phase II NOBILITY study, investigating the safety and efficacy of Gazyva (obinutuzumab) for adults with proliferative lupus nephritis.

Innovation - Health - 06.11.2019
ETH plans competence centre for holistic rehabilitation
ETH plans competence centre for holistic rehabilitation
ETH researchers are planning to partner with clinics, foundations, public authorities and other institutions through a broad-based initiative aimed at improving the quality of life and participation of people with physical disabilities.

Life Sciences - Health - 05.11.2019
EPFL bioengineering team wins global iGEM competition
EPFL bioengineering team wins global iGEM competition
EPFL's student bioengineering team has won the Grand Prize of the 2019 International Genetically Engineered Machine (iGEM) competition, as well as the Best Environment Project.

Pharmacology - Health - 01.11.2019
Novartis Cosentyx shows encouraging results versus Humira * from first-of-its-kind head-to-head trial in psoriatic arthritis
Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira *   Statistically signifi

Pharmacology - Health - 30.10.2019
Roche’s marketing applications for satralizumab in neuromyelitis optica spectrum disorder accepted for review by EMA and FDA
Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis European Medicines A

Health - Life Sciences - 28.10.2019
The Center for Biomedical Imaging marks its 15th anniversary
The Center for Biomedical Imaging marks its 15th anniversary
For the past decade and a half, the Center for Biomedical Imaging (CIBM) has been bringing researchers and clinicians together to develop cutting-edge technologies. This anniversary is an opportunity to reflect on the Center's past successes and ponder the challenges that lie ahead in the field of medical imaging.

Materials Science - Health - 24.10.2019
Closer to the patient
Closer to the patient
The first national competence centre for translational medicine and entrepreneurship has opened in Bern. As a hub for research and innovation, "sitem-insel" is home to several start-ups, companies and scientists. These include an Empa research team whose projects aim to bring medical innovations from the laboratory directly to patients more quickly.

Health - Innovation - 22.10.2019
EPFL spin-off GTX medical moves into the US market
EPFL spin-off GTX medical moves into the US market
GTX medical, an EPFL spin-off that has developed an implantable neuromodulation therapy to help people with spinal cord injuries walk again, merged today with NeuroRecovery Technologies, a US-based company, developing a transcutaneous stimulation therapy to improve upper limb function after a SCI.

Pharmacology - Health - 21.10.2019
Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer Data will be submitted to

Health - Pharmacology - 18.10.2019
Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications
Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control

Health - Life Sciences - 18.10.2019

Health - Life Sciences - 16.10.2019
ETH scores highly on interdisciplinarity
Two ETH Zurich projects and one with ETH involvement have been awarded one of the coveted ERC Synergy Grants. These EU grants offer up to EUR 14 million to promote interdisciplinary collaboration on research projects. Correlations and questions in research are becoming more and more complex, which makes collabo-ration between researchers from different fields necessary.

Pharmacology - Health - 14.10.2019
Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris 40% of patients with pemphigus vulgaris (PV) achieved sustaine

Health - Life Sciences - 11.10.2019
ERC Synergy Grant for research at the interface of viral infection and cellular regulation
ERC Synergy Grant for research at the interface of viral infection and cellular regulation
The European Research Council has awarded one of the prestigious ERC Synergy Grants - the most competitive funding scheme from ERC - to a joint research project of the Friedrich Miescher Institute for Biomedical Research, the ETH Zurich and the University of Bristol. The interdisciplinary team wants to investigate the molecular mechanisms of viral infection, which will contribute to fundamental knowledge about cellular regulation and new concepts for broad-spectrum anti-viral therapy.

Health - Life Sciences - 11.10.2019
ERC Synergy Grant for viral infection and cellular regulation research
The European Research Council has awarded one of the prestigious ERC Synergy Grants - the most competitive funding scheme from ERC - to a joint research project of the Friedrich Miescher Institute for Biomedical Research, the ETH Zurich and the University of Bristol. The interdisciplinary team wants to investigate the molecular mechanisms of viral infection, which will contribute to fundamental knowledge about cellular regulation and new concepts for broad-spectrum anti-viral therapy.

Health - Life Sciences - 08.10.2019
Prostate cancer research, important SNF grant goes to the IOR
The Prostate cancer biology Group, led by Dr. Giuseppina Carbone at the Institute of Oncology Research (IOR, affiliated to USI Università della Svizzera italiana), has received a 4-year grant

Pharmacology - Health - 08.10.2019
Novartis receives FDA approval for Beovu , offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients

Pharmacology - Health - 02.10.2019
Novartis positive 52-week PREVENT data confirm Cosentyx efficacy in addressing entire axSpA spectrum
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)   Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.

Pharmacology - Health - 01.10.2019
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized Novartis to establish

Pharmacology - Health - 30.09.2019
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the fi
1 2 3 4 5 ... 34 Next »